Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease

Hansa Biopharma said its global pivotal Phase 3 GOOD-IDES-02 trial in anti‑GBM disease did not meet the primary endpoint of renal function (eGFR) at six months, after randomizing 50 patients (25 imlifidase + standard of care (SoC), 25 SoC alone); although ~60% of the imlifidase arm avoided dialysis at six months—substantially higher than the 20–25% typically seen in historical cohorts—the control arm receiving aggressive SoC (immediate plasma exchange, cyclophosphamide and glucocorticoids) produced similar results so the difference was not statistically significant. Imlifidase was well tolerated with an acceptable safety profile and patients will be followed to 24 months, but the outcome is a clear setback for an anti‑GBM approval pathway; Hansa nonetheless highlighted the encouraging dialysis‑avoidance signal and said it remains on track to file a BLA this year for imlifidase’s desensitization use in highly sensitized kidney transplant candidates.

Analysis

Hansa Biopharma reported that the global pivotal Phase 3 GOOD-IDES-02 trial in anti-GBM disease did not meet its primary endpoint of renal function (eGFR) at six months after randomizing 50 adults (25 imlifidase+SoC, 25 SoC alone). Approximately 60% of patients in the imlifidase arm avoided dialysis at six months versus historical benchmarks of 20–25%, but the control arm treated with an aggressive, protocol-defined standard of care (immediate plasma exchange, cyclophosphamide and glucocorticoids) produced similar outcomes and eliminated a statistically significant treatment difference.

The study was open-label across more than 50 sites in 14 countries and was powered against historical controls; the small sample (n=50) and the use of an intensive SoC comparator likely reduced the ability to detect incremental eGFR benefit despite a marked dialysis-avoidance signal. Safety was described as acceptable and consistent with prior imlifidase data, and patients will be followed to 24 months with long-term outcomes pending.

Missing the primary endpoint is a clear regulatory setback for an anti-GBM indication, yet the dialysis-avoidance signal and tolerability sustain a rationale for further work; management remains on track to file a BLA this year for the desensitization kidney-transplant indication, creating a nearer-term potential value catalyst to watch alongside the 24-month readout and regulator feedback.

Key Decisions for Investors

• Reduce near-term exposure or hedge HNSA positions given the missed primary endpoint weakens the anti-GBM approval case and uncertainty will likely pressure sentiment until longer-term data or regulatory clarity emerges
• Monitor three near-term catalysts closely—the 24-month follow-up readout, the company’s planned BLA filing for desensitization (on track before year-end), and any FDA/EMA feedback—and only re-engage materially if regulators accept the dialysis-avoidance signal or long-term endpoints improve
• If maintaining a position, consider size discipline or protective option strategies to preserve upside from potential label expansion or positive BLA outcomes while limiting downside from continued negative sentiment or regulatory setbacks